OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacogenomics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Identification of RNA Modification-Associated Single-Nucleotide Polymorphisms in Genomic Loci for Low-Density Lipoprotein Cholesterol Concentrations	36
Pharmacogenomics in Psychiatry – the Challenge of Cytochrome P450 Enzyme Phenoconversion and Solutions to Assist Precision Dosing	27
Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization	26
miR-369-3p regulates the drug resistance of lung cancer cells by targeting PTPN12	23
Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications	22
A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level	22
Severe systemic Adverse Reactions to Ophthalmic Timolol in a CYP2D6 Homozygous *4 Allele Carrier: A Case Report	21
Pharmacogenetics of Sulfonylurea-Induced Hypoglycemia in Type 2 Diabetes Patients: the SUCLINGEN Study	21
Rapid point of care testing: the next frontier in pharmacogenomics	19
Characterization of CYP2C19 Pharmacogenetic Variation in African Populations and Comparison with Other Global Populations	17
Integrated in a Systems Pharmacology Approach, Pharmacogenetics holds the Promise for Personalized Medicine in Neonates	17
Contrasting ABCB1 Pharmacogenetics and Psychotropic Responses in Child and Adolescent Psychiatry: A case comparison	16
Gene Polymorphisms Affect Postoperative Imatinib Plasma Levels and Edema in Adults With Gastrointestinal Stromal Tumor	14
CYP2D6 Gene Resequencing in the Malagasy, a Population at the Crossroads between Asia and Africa: A Pilot Study	14
Pharmacogenetic markers and macrolide safety in influenza patients: insights from a prospective study	12
Workforce readiness for pharmacogenomics and key elements for sustainment within the Veterans Health Administration	12
A Survey of Physician Opinions in Russia in the Field of Pharmacogenetics of Cardiovascular Disease	12
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics	11
EFfects of UGT1A , CYP2C9/19 and ABAT Polymorphisms on Plasma Concentration of Valproic Acid in Chinese Epi	11
Association of NAT-2 Gene Polymorphisms Toward Lung Cancer Susceptibility and Prognosis in North Indian Patients Treated with Platinum-Based Chemotherapy	11
Multiple Genetic Mutations Increase the Risk of Thrombosis Associated With Clopidogrel After Percutaneous Coronary Intervention	11
Genetic polymorphisms and adverse reactions to antituberculosis therapy	11
The Promise�of Digital Health in Healthcare Equity and Medication Adherence in the Disadvantaged Dementia Population	10
The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma	10
Improving the Management of ALK-Rearranged Non-Small-Cell Lung Cancer Through a Mobile Application: A Physicians-Based Survey	10

UGT1A1 Genotype-Guided Dosing of Irinotecan: Time to Prioritize Patient Safety	10
Methods for Actionable Gene Fusion Detection in Lung Cancer: Now and in the Future	10
Cost–Effectiveness of HLA-B58:01* Testing to Prevent Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in Vietnam	10
A critical review of RAF inhibitors in BRAF-mutated glioma treatment	9
Impact of genetic variants on fentanyl metabolism in major breast surgery patients: a candidate gene association study	9
Genetic Factors Associated with Tuberculosis-Related Clinical Outcomes in HIV-Infected Black African Patients: a Systematic Review and Meta-Analysis	9
Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review	8
The Festival of Genetics and Personalized Medicine	8
Effects of CYP3A4 and CYP2C9 Genotype on Systemic Anastrozole and Fulvestrant Concentrations in SWOG S0226	8
Genetika+: Precision Medicine Solutions for Mental Health	8
Carbamazepine Cutaneous Adverse Reactions and HLA Gene Variation in the Chinese Population: A Systematic Review and Meta-Analysis	8
Head-to-head Comparison of Various Antipsychotic Agents on Genome-Wide Methylation in Schizophrenia	8
TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience	8
Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations	7
Predicting laboratory aspirin resistance in Chinese stroke patients using machine learning models by GP1BA polymorphism	7
DDX11-AS1 Modulates Dna Damage Repair to Enhance Paclitaxel Resistance of Lung Adenocarcinoma Cells	7
Association between CYP3A4 , CYP3A5 and ABCB1 Genotype and Tacrolimus Treatment Outcomes Among Allogeneic H	7
Barriers and facilitators for implementing a pharmacogenetic passport: lessons learned from reusing sequencing data	7
Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients	7
SLCO1B1 and ABCB1 Variants Synergistically Influence the Atorvastatin Treatment Response in South Indian Coronary Artery Disease Patients	7
Polymorphisms of Genes Related to Phase II Metabolism and Resistance to Clopidogrel	6
Knowledge and Attitudes of Incoming Pharmacy Students Toward Pharmacogenomics and Survey Reliability	6
Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases	6
Erratum	6
Glutathione S -transferase Gene Polymorphism and Asthma: A Case–Control Study in a Pediatric Population	6
Pharmacogenomics in Pediatric Medicine and Drug Development	6
DPYD Genotyping and Predicting Fluoropyrimidine Toxicity: Where do we Stand?	6
Genetic risk factors for drug-induced long QT syndrome: findings from a large real-world case–control study	6
Donor-Derived Cell Free DNA as a Biomarker in Kidney Transplantation	6
XDH Genotypes Through Gene–Gene Interactions with NUDT15 Affect Azathioprine-Induced Leukopenia in Chinese Patients	6
Pharmacogenomics: A Tool to Improve Medication Safety and Efficacy in Patients with Cystic Fibrosis	5
Patient Satisfaction With Return of Pharmacogenomic Results Utilizing a Patient Portal Message	5
Impact of CYP2C19 Gene Polymorphisms on Warfarin Dose Requirement: A Systematic Review and Meta-Analysis	5
The Frequency Of Rs2231142 in ABCG2 Among Native Hawaiian nd Pacific Islander Subgroups: Implications for Personalized Rosuvastatin Dosing	5
Relevance of NAT2 Genotype and Clinical Factors to Risk for Antituberculosis Drug-Induced Liver Injury	5
Overview of the Year 2023 at Pharmacogenomics	5
Posttransplantation diabetes mellitus (PTDM): pharmacological aspects and genetic predispositions	5
Bioinformatic Tools are Essential to Integrating Pharmacogenomics into Clinical Practice: Lessons from Neuropsychiatric Disorders	5
The Effects of Sex on Pharmacogenetically Guided Drug Treatment	5
The Revolution of Pharmaco-Omics: Ready to Open new Avenues in Materializing Precision Medicine?	5
Dosage Optimization of Clopidogrel Via a Precision Medicine Approach: The Way Forward	5
Pharmacogenomic Study of Anthracycline-Induced Cardiotoxicity in Mexican Pediatric Patients	5
Polymorphisms in the CYP3A5 Gene Significantly Affect the Pharmacokinetics of Sirolimus After Kidney Transplantation	5
Genetic polymorphisms of OPRM1 on the Efficacy and Safety of Anesthetic and Analgesic Agents: A Systematic Review	5
The Genetics of Drug-Induced Qt Prolongation: Evaluating the Evidence for Pharmacodynamic Variants	5
Relevance of NR1I2 Variants on Carbamazepine Therapy in Mexican Mestizos with Epilepsy at a Tertiary-Care Hospital	5
Influence of CYP3A5 , IL-10 Polymorphisms and Metabolism Rate on Tacrolimus Exposure in Renal Post-Transplant Recipients	5
Impact of ABCB1 gene polymorphism on clopidogrel plasma concentration and cardiovascular events in post-PCI patients	5
Pharmacogenomic curriculum in Australian medical schools: a content analysis study	5
Pharmacogenomic Prescribing Opportunities in Percutaneous Coronary Intervention and Bone Marrow Transplant Patients	4

Leveraging Clinical Decision Support to Reduce the Risk of Discordant Pharmacogenomics Results	4
Single-Nucleotide Polymorphisms in ABC Drug Transporters Alter Expression and Circulating Tenofovir in Healthy South African Women Exposed to Pre-Exposure Prophylaxis	4
Genome-Wide Association Study of Liver Enzyme Elevation in an Extended Cohort of Rheumatoid Arthritis Patients Starting Low-Dose Methotrexate	4
Congruence Rates for Pharmacogenomic Noninterruptive Alerts	4
Association of CYP2C19 , CYP3A4 and ABCC2 Polymorphisms and Voriconazole Plasma Concentrations in Uygur Ped	4
Pharmacogenomics education among professional societies: assessing practices and future needs	4
Influence of Polymorphisms in CYP2C9 , VKORC1 , MDR1 and APOE Genes on the W	4
KCNQ1 Variant rs163184 is a Potential Biomarker of Glycemic Response to Exenatide	4
Pharmacogenetics of HIV Therapy: Challenges for Tailoring Treatment in Genetically Complex Populations	4
Pharmacogenetics of Calcineurin inhibitors in kidney transplant recipients: the African gap. A narrative review	4
SLCO1B3 Polymorphisms and Clinical Outcomes in Kidney Transplant Recipients Receiving Mycophenolate	4
Psychiatric Level 1A Evidence Pharmacogenomics in a Brazilian Admixed Cohort and Global Populations	4
Evaluation of Pentamidine Tolerability and Efficacy Between CYP2C19 Phenotypes	4
ATP Binding Cassette Transporters and Cancer: Revisiting Their Controversial Role	4
Artificial intelligence, medications, pharmacogenomics, and ethics	4
The Importance of Phenoconversion when using the CYP2D6 Genotype in Clinical Practice	4
Clinical Pharmacology and Pharmacogenomics for Implementation of Personalized Medicine	4
Healthcare Professionals’ Knowledge, Confidence and Perceptions of Pharmacogenomics in Primary Care and Pain Management	4
Effect of UGT1A6 and UGT2B7 polymorphisms on the valproic acid serum concentration and drug-induced liver injury	4
Engaging Pharmacogenomics in Pain Management and Opioid Selection	4
lncRNA MALAT1 Regulates the Resistance of Breast Cancer Cells to Paclitaxel Via the miR-497-5p/ SHOC2 axis	4
Pharmacogenomics Implementation: “ A Little Less Conversation, a Little More Action, Please ”	4